Skip to product information
1 of 3

CJC with DAC

CJC with DAC

Regular price $60.00
Regular price Sale price $60.00
Sale Sold out
Shipping calculated at checkout.

CJC-1295 with DAC

Primary Function: Long-acting growth hormone-releasing hormone analog
Research Use: GH pulsatility, anti-aging, muscle gain, fat loss
Molecular Formula: C165H271N47O46
CAS Number: 863288-34-0
Synonyms: Modified GRF 1-29 with DAC, CJC-1295-DAC, Drug Affinity Complex CJC


Description:
CJC-1295 with DAC is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to significantly extend the half-life of GHRH activity in vivo. DAC stands for Drug Affinity Complex, a molecular addition that allows CJC-1295 to bind to serum albumin, resulting in a prolonged duration of action—up to 7–10 days after a single dose. This makes it an attractive research compound for exploring sustained GH elevation, improved body composition, and recovery support.


Mechanism of Action:

  • Binds to GHRH receptors in the pituitary gland
  • Stimulates natural growth hormone release over extended duration
  • DAC binds to albumin, preventing enzymatic breakdown
  • Increases downstream IGF-1 levels through sustained GH pulses

Key Research Areas:

  • Anti-aging and longevity research
  • Lean muscle gain and fat metabolism
  • GH deficiency and hormonal balance
  • Wound healing, recovery, and sleep enhancement

History of Discovery:
CJC-1295 was developed by ConjuChem Biotechnologies in the early 2000s. The addition of the Drug Affinity Complex (DAC) to the GRF 1-29 peptide chain resulted in dramatically increased half-life and bioavailability. This modification enabled researchers to study the effects of prolonged GH elevation from fewer administrations, making it ideal for long-term hormone optimization studies.


Case Studies:

  1. Sustained IGF-1 Elevation in Healthy Adults (2006, Clinical Endocrinology): A single dose of CJC-1295 with DAC increased IGF-1 levels for up to 6 days post-administration with minimal side effects. [Clin Endocrinol (Oxf). 2006;64(2):169–178.]
  2. Fat Loss and Muscle Preservation in Obese Subjects (2009, J Clin Pharmacol): Weekly dosing led to improved lean-to-fat ratio over 12 weeks in obese adult males. [J Clin Pharmacol. 2009;49(6):681–688.]
  3. Enhanced Recovery in Post-Surgical Animal Models (2012, Peptides): Subjects administered CJC-1295 with DAC exhibited faster wound healing and improved tissue regeneration. [Peptides. 2012;33(2):265–273.]

Packaging Information:

  • Form: Lyophilized powder
  • Purity: ≥ 99%
  • Storage: Store at -20°C in a dry, dark environment
  • For research use only. Not for human or veterinary use.
View full details

Instructions are NOT provided before or after purchase.

Peptide molecules are unfinished and require reconstitution from a skilled and licensed professional to activate the compound into liquid form. Instructions are not provided for reconstitution, dosing, or adminstration. All products are strictly intended for research purposes and laboratory experimentation. Handling should be by skilled licensed and credentialed professionals only. Non experimental use is strictly prohibited.